Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly hopes that a new pill it's developing can do everything Ozempic can without the hassles. It's called orforglipron (put the emphasis on the second syllable: or-FOUR-glip-ron).

Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz Jared Holz, Mizuho, ...

The news has put pressure on Eli Lilly, whose shares fell as the market reacted to the potential challenge to its obesity drug, Zepbound, also known as Mounjaro. Despite earlier success ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Shares of pharmaceutical giant Eli Lilly (NYSE:LLY) edged down 1.2% in premarket trading following announcements from ...